Published in Allergy Asthma Clin Immunol on July 28, 2010
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol (2010) 2.75
Safe anticoagulation when heart and lungs are "on vacation". Ann Transl Med (2015) 0.79
Recent developments in the treatment of acute abdominal and facial attacks of hereditary angioedema: focus on human C1 esterase inhibitor. Appl Clin Genet (2010) 0.75
Using a bradykinin blocker in ACE inhibitor-associated angioedema in the emergency department. BMJ Case Rep (2013) 0.75
The first probable case of hereditary angioedema in Vietnam. Allergy Asthma Immunol Res (2012) 0.75
Hereditary angioedema type III (estrogen-dependent) report of three cases and literature review. An Bras Dermatol (2013) 0.75
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest (1990) 10.35
Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med (1976) 2.96
Hereditary angioedema with normal C1-inhibitor activity in women. Lancet (2000) 2.65
Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol (2000) 2.07
C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol (1988) 1.80
Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol (2008) 1.76
Specific binding of estrogen receptor to the estrogen response element. Mol Cell Biol (1989) 1.61
Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol (2007) 1.52
Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol (2004) 1.48
Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet (2006) 1.45
Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet (1969) 1.36
Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun (2006) 1.34
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet (2005) 1.29
Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol (2009) 1.20
Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med (1980) 1.12
Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther (2002) 1.12
Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med (2007) 1.02
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology (1999) 1.01
Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. J Allergy Clin Immunol (2009) 1.00
Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol (2009) 0.98
Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. J Allergy Clin Immunol (2001) 0.96
Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology (1995) 0.95
Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol (2006) 0.94
Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment. Allergy (2007) 0.93
Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice. Am J Physiol Heart Circ Physiol (2002) 0.92
Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. J Allergy Clin Immunol (2007) 0.89
Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol (2007) 0.88
The pathogenesis of hereditary angioedema. Transfus Apher Sci (2003) 0.88
Angioedema and estrogen-dependent angioedema with activation of the contact system. J Allergy Clin Immunol (2009) 0.86
A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol (2007) 0.86
Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol (Oxf) (2004) 0.86
Gonadal effects on plasma ACE activity in mice. Atherosclerosis (2002) 0.85
Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther (2000) 0.85
Bradykinin metabolism and hypotensive transfusion reactions. Transfusion (2001) 0.81
Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol (2004) 0.81
C1 esterase inhibitor in pregnancy. J Allergy Clin Immunol (1992) 0.81
[Obstetric analgesia for a women with type III hereditary angioneurotic edema]. Rev Esp Anestesiol Reanim (2007) 0.80
First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology (2008) 0.80
C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost (1991) 0.80
C1 inactivator level in pregnancy. Thromb Res (1982) 0.80
Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. J Lab Clin Med (1988) 0.79
Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors. Kidney Int (2006) 0.79
Effect of dienogest on bleeding time, coagulation, fibrinolysis, and platelet aggregation in female rats. Toxicol Lett (1999) 0.78
Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen--levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb Haemost (1985) 0.77
Hormone binding globulin levels in patients with hereditary angiooedema during treatment with Danazol. Clin Endocrinol (Oxf) (1981) 0.76